CareRx Pfcf Ratio vs Price To Sales Ratio Analysis
CRRX Stock | CAD 1.89 0.01 0.53% |
CareRx Corp financial indicator trend analysis is way more than just evaluating CareRx Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CareRx Corp is a good investment. Please check the relationship between CareRx Corp Pfcf Ratio and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CareRx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Pfcf Ratio vs Price To Sales Ratio
Pfcf Ratio vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CareRx Corp Pfcf Ratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have weak relationship.
The correlation between CareRx Corp's Pfcf Ratio and Price To Sales Ratio is 0.32. Overlapping area represents the amount of variation of Pfcf Ratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of CareRx Corp, assuming nothing else is changed. The correlation between historical values of CareRx Corp's Pfcf Ratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pfcf Ratio of CareRx Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Pfcf Ratio i.e., CareRx Corp's Pfcf Ratio and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Pfcf Ratio
Price To Sales Ratio
Price to Sales Ratio is figured by comparing CareRx Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CareRx Corp sales, a figure that is much harder to manipulate than other CareRx Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from CareRx Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CareRx Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CareRx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, CareRx Corp's Issuance Of Capital Stock is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Over EBITDA is likely to grow to 7.80, while Selling General Administrative is likely to drop about 28.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 262.6M | 381.7M | 370.7M | 389.3M | Depreciation And Amortization | 15.4M | 20.1M | 20.0M | 13.2M |
CareRx Corp fundamental ratios Correlations
Click cells to compare fundamentals
CareRx Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CareRx Corp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 87.1M | 156.1M | 282.8M | 264.5M | 231.9M | 178.4M | |
Total Current Liabilities | 68.0M | 43.3M | 53.0M | 63.9M | 62.4M | 60.0M | |
Total Stockholder Equity | (20.0M) | 11.3M | 82.3M | 64.5M | 81.5M | 85.6M | |
Net Debt | 66.2M | 62.6M | 89.9M | 106.9M | 89.8M | 92.7M | |
Retained Earnings | (201.9M) | (220.2M) | (242.9M) | (277.3M) | (282.7M) | (268.6M) | |
Accounts Payable | 11.8M | 16.4M | 33.2M | 30.5M | 29.1M | 17.0M | |
Cash | 61K | 19.6M | 35.6M | 28.4M | 7.7M | 6.6M | |
Non Current Assets Total | 68.0M | 110.9M | 187.6M | 175.4M | 166.5M | 125.6M | |
Non Currrent Assets Other | (68.0M) | (110.9M) | (187.6M) | (175.4M) | (157.8M) | (149.9M) | |
Cash And Short Term Investments | 61K | 19.6M | 35.6M | 28.4M | 7.7M | 6.7M | |
Net Receivables | 12.6M | 15.4M | 38.1M | 37.3M | 36.1M | 22.2M | |
Common Stock Shares Outstanding | 11.0M | 20.3M | 34.9M | 47.6M | 57.3M | 60.2M | |
Liabilities And Stockholders Equity | 87.1M | 156.1M | 282.8M | 264.5M | 231.9M | 178.4M | |
Other Stockholder Equity | 30.1M | 41.7M | 41.8M | 34.5M | 33.6M | 33.0M | |
Total Liab | 107.0M | 144.8M | 200.5M | 200.1M | 150.4M | 156.1M | |
Total Current Assets | 19.1M | 45.2M | 95.2M | 89.2M | 65.4M | 52.8M | |
Short Long Term Debt Total | 66.2M | 85.8M | 131.4M | 135.2M | 97.5M | 139.4M | |
Other Current Liab | 3.8M | 20.9M | 18.5M | 23.4M | 21.0M | 15.5M | |
Property Plant And Equipment Net | 20.0M | 21.1M | 38.2M | 52.4M | 52.1M | 54.7M | |
Other Current Assets | 1.3M | 1.6M | 3.5M | 2.6M | 2.0M | 1.9M | |
Property Plant And Equipment Gross | 20.0M | 21.1M | 56.6M | 74.0M | 78.9M | 82.8M | |
Accumulated Other Comprehensive Income | 10.8M | (18.4M) | 9.4M | 7.5M | 7.3M | 7.7M | |
Short Term Debt | 45.6M | 6.1M | 1.3M | 10.0M | 12.4M | 11.8M | |
Intangible Assets | 18.7M | 35.3M | 54.6M | 53.0M | 44.3M | 43.7M | |
Good Will | 27.2M | 51.7M | 92.1M | 70.0M | 80.5M | 77.9M | |
Current Deferred Revenue | 11K | 6.9M | 17.3M | 13.1M | 15.1M | 15.8M | |
Non Current Liabilities Total | 39.0M | 101.5M | 147.6M | 136.2M | 87.9M | 102.5M | |
Inventory | 5.2M | 8.6M | 18.0M | 20.3M | 19.7M | 12.3M | |
Common Stock | 141.1M | 189.8M | 283.5M | 299.8M | 323.3M | 184.6M | |
Long Term Debt | 13.0M | 71.9M | 112.0M | 99.4M | 57.1M | 59.3M | |
Long Term Debt Total | 20.6M | 79.7M | 130.2M | 125.2M | 112.7M | 67.1M | |
Capital Surpluse | 30.1M | 31.4M | 32.3M | 34.5M | 39.7M | 32.0M | |
Property Plant Equipment | 20.0M | 21.1M | 38.2M | 52.4M | 60.3M | 63.3M | |
Other Liab | 18.4M | 21.7M | 17.4M | 11.0M | 9.9M | 15.6M | |
Net Tangible Assets | (65.9M) | (75.8M) | (64.4M) | (58.5M) | (67.3M) | (70.6M) | |
Capital Lease Obligations | 9.0M | 9.6M | 18.7M | 28.4M | 30.8M | 32.3M | |
Short Long Term Debt | 44.3M | 4.2M | 733K | 7.4M | 9.9M | 9.4M | |
Non Current Liabilities Other | 2.5M | 4.0M | 2.6M | 3.7M | 2.8M | 2.6M | |
Cash And Equivalents | 61K | 19.6M | 35.6M | 28.4M | 32.6M | 34.3M |
Other Information on Investing in CareRx Stock
Balance Sheet is a snapshot of the financial position of CareRx Corp at a specified time, usually calculated after every quarter, six months, or one year. CareRx Corp Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of CareRx Corp and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which CareRx currently owns. An asset can also be divided into two categories, current and non-current.